Neuraxis prelim Q3: net sales $0.8M; cash $4.4M

Rhea-AI Filing Summary

Neuraxis, Inc. disclosed preliminary, unaudited results for the quarter and nine months ended September 30, 2025. The company expects cash and cash equivalents of approximately $4.4 million as of September 30, 2025.

For the three months ended September 30, 2025, Neuraxis estimates net sales of about $0.8 million, gross profits of about $0.7 million, and an operating loss of about $2.1 million. For the nine months ended September 30, 2025, net sales are expected to be about $2.6 million, compared with about $1.9 million for the same period in 2024.

Management emphasized these figures are preliminary and subject to change as the quarter-end close is completed. The company’s independent registered public accounting firm has not audited or reviewed these estimates, and final financial statements will be completed subsequent to this report. The company cautioned that adjustments could be material and advised against undue reliance on these preliminary figures.

Insights

Equity analyst

Preliminary Q3 shows modest sales and a sizable operating loss; neutral.

Neuraxis pre-announced Q3 metrics: net sales around $0.8M, gross profit near $0.7M, and an operating loss of about $2.1M. Cash was approximately $4.4M as of September 30, 2025, providing a snapshot of liquidity at quarter-end.

For the nine months, net sales were approximately $2.6M versus $1.9M in the prior-year period, indicating growth in top-line run-rate within the year-to-date window. These figures are unaudited and prepared by management; the auditor has not performed procedures.

Actual reported results may differ as the company completes its close and finalizes financial statements subsequent to this 8-K. The investment impact hinges on finalized results and any updates to operating trends once the full quarterly report is released.

false 0001933567 0001933567 2025-10-23 2025-10-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 23, 2025

Neuraxis, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41775		45-5079684
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

11611 N. Meridian St, Suite 330 Carmel, IN 46032

(Address of principal executive offices)

Registrant’s telephone number, including area code: (812) 689-0791

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		NRXS		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On October 23, 2025, Neuraxis, Inc. (the “Company”), issued disclosure that, on a preliminary unaudited basis, the Company expects its cash and cash equivalents to be approximately $4.4 million as of September 30, 2025. On a preliminary unaudited basis, the Company expects its net sales to be approximately $0.8 million, its gross profits to be approximately $0.7 million, and its operating loss to be approximately $2.1 million, for the three months ended September 30, 2025. On a preliminary unaudited basis, the Company expects its net sales for the nine months ended September 30, 2025 to be approximately $2.6 million as compared to approximately $1.9 million for the nine months ended September 30, 2024. As the Company completes its quarter-end financial statement close process and finalizes its financial statements and accompanying notes for the three and nine months ended September 30, 2025, the Company will be required to make significant judgments in a number of areas that may result in the estimates provided herein being different than the final reported amounts.

These preliminary estimates have been prepared by and are the responsibility of the Company’s management. The Company’s independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to these preliminary estimates or the accounting treatment thereof and does not express an opinion or any other form of assurance with respect thereto. The Company expects to complete its financial statements for the three and nine months ended September 30, 2025 subsequent to the filing of this Item 2.02 8-K. It is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to these preliminary estimates and those changes could be material. Accordingly, undue reliance should not be placed on these preliminary estimates.

The information contained in Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and such information is not incorporated by reference into any registration statements or other document filed under the Securities Act of 1933, as amended or the Exchange Act, regardless of the general incorporation language contained in such filing, except as shall be expressly set forth by specific reference to this filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 23, 2025	NEURAXIS, INC.
	By:	/s/ Brian Carrico
	Name:	Brian Carrico
	Title:	President and Chief Executive Officer

FAQ

What did Neuraxis (NRXS) report for preliminary Q3 2025 results?

The company estimates Q3 net sales of about $0.8 million, gross profits of about $0.7 million, and an operating loss of about $2.1 million.

How much cash did Neuraxis (NRXS) have as of September 30, 2025?

Neuraxis expects cash and cash equivalents of approximately $4.4 million as of September 30, 2025.

How did nine-month 2025 net sales compare year over year for NRXS?

For the nine months ended September 30, 2025, net sales are about $2.6 million versus about $1.9 million for the same period in 2024.

Are Neuraxis’ preliminary results audited or reviewed by the auditor?

No. These are preliminary, unaudited estimates; the independent auditor has not audited, reviewed, or performed procedures.

Will Neuraxis (NRXS) update these figures with final results?

Yes. The company plans to complete and file its financial statements for the period subsequent to this report.

Did Neuraxis give any caution about relying on these estimates?

Yes. The company warned that adjustments could be material and advised against undue reliance on the preliminary figures.